A pioneering mRNA cancer vaccine is delivering high hopes for patients with advanced lung cancer as a major international trial gains momentum. The First Department of Medical Oncology at Agios Savvas Hospital in Greece has emerged as a global leader in the study, currently ranking second worldwide for patient recruitment.
Alexandros Ardavanis, the department’s director and scientific lead, confirmed that the Phase 3 randomised trial focuses on patients with non-small cell lung cancer who have stopped responding to standard immunotherapy. This therapeutic vaccine aims to re-energise the body’s immune response. “Preliminary data suggests we can further extend survival rates in advanced cases,” Ardavanis stated, noting the trial began nine months ago and should conclude by 2028.
Twelve Greek centres—eight of them in the public sector—are participating in this global push to evolve immunotherapy. The surge in clinical trials follows the recent certification of Agios Savvas as Greece’s first Comprehensive Cancer Center. Founded in 1935 as the nation’s first dedicated cancer facility, the hospital received a state funding boost last year to secure this status.
This certification has directly expanded patient access to cutting-edge medicines. Ardavanis believes the medical community is entering a transformative era, stating that while it is early to measure the full impact of mRNA technology on malignancies, the current results offer extreme optimism for the future of cancer care.
